Skip to content

Innate Pharma SA

IPHA· NasdaqCore metricsCIK 1598599

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -5.66%
Market cap
$140.58M
93.72M shares
Filings
340
€9.01M
FY 2025−55.2% FY25 yoy
-€49.18M
FY 2025N/M FY25 yoy
-€54.01M
FY 2025N/M FY25 yoy
-€52.90M
FY 2025derivedN/M FY25 yoy
-€0.55
FY 2025N/M FY25 yoy
€28.09M
FY 2025−57.7% FY25 yoy
$140.58M
—
—
—
—
—

Price

$1.5029.91%$0.64past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

€9.01MFY 2025
€93.95M0FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31€9,005,000reported
FY 20242024-12-31€20,121,000reported
FY 20232023-12-31€61,641,000reported
FY 20222022-12-31€57,674,000reported
FY 20212021-12-31€24,703,000reported
FY 20202020-12-31€69,773,000 revisedreported
FY 20192019-12-31€85,449,000 revisedreported
FY 20182018-12-31€93,952,000reported
FY 20172017-12-31€44,033,000reported

Biological products, except diagnostic substances

Innate Pharma SA is the 104th largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Innate Pharma SA · CIK 1598599 · Engraved from SEC EDGAR